Cardio Diagnostics' PrecisionCHD Test To Detect Hidden Forms Of Heart Disease INOCA And MINOCA, To Be Presented At AHA Sessions

Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) are two underdiagnosed, potentially fatal forms of heart disease that standard diagnostic testing routinely fails to detect

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered Precision Cardiovascular Medicine company, today announced that the Company will be presenting new data at the American Heart Association (AHA) Scientific Sessions demonstrating that the epigenetic biomarkers of the Company's PrecisionCHD test are able to detect Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) presentations. PrecisionCHD is an integrated epigenetic-genetic blood test that aids in the diagnosis of coronary heart disease (CHD). The AHA Scientific Sessions will take place in New Orleans, LA, from November 7 to 10.

A Critical Gap in Cardiovascular Diagnostics

CHD is the most common type of cardiovascular disease (CVD), is the primary cause of heart attacks, and remains a leading cause of death in the United States. The diagnosis of CHD is traditionally focused on the obstructive form of the disease. However, research shows that approximately 30 to 50 percent of patients referred for invasive coronary angiography have INOCA and up to 10 percent of all myocardial infarctions are MINOCA. INOCA is more frequently observed in women. Unfortunately, without access to expensive invasive provocative testing at highly specialized testing centers, INOCA goes undiagnosed and untreated. As a result, tens of thousands of patients needlessly suffer premature mortality and nonfatal myocardial infarctions annually.